Gary Rojewski has 29-years experience in the pharmaceutical industry. During that time he has worked for Procter & Gamble Pharmaceuticals, Warner Chilcott Pharmaceuticals and most recently Actavis. Throughout his pharmaceutical career he has been responsible for commercializing pharmaceutical products.
CEO – Gary Rojewski
LATEST ENZYME BIOSYSTEMS PRESS RELEASE & NEWS
Pipeline – Sarcomycin
ENZB, designed a drug delivery mechanism, whereby a series of semisynthetic penicillins and cephalosporins containing structural fragments of sarcomycin have been synthesized. Sarcomycin has been around for many years. It is an anti-tumor antibiotic. The problem, is that when it is taken by a cancer patients, and the sarcomycin is given alone, it does not attached to the tumor, but moves throughout the entire body. The penicillin delivers the sacromycin to the tumor where the penicillin attaches to the tumor as proteinase and delievers the sacromycin directly into the tumor.
Breast cancer represents the most frequently diagnosed cancer and leading cause of cancer deaths in females worldwide. Approximately, 1.4 million new cases of breast cancer and 458,400 deaths in females due to this disease are estimated to have occurred in 2008 (Jemal et al., 2011). Highest rates of breast cancer occur in North America, western Europe and Australia, nevertheless, the incidence is increasing in all parts of the globe, especially in the developing countries. The preponderance of breast cancer is sporadic and the risk factors are predominantly linked to estrogen exposure and age. Steroid hormones, particularly estrogen, contribute to the development and progression of mammary gland neoplasia. Genetic factors, including mutations in BRCA 1 and BRCA 2, contribute to approximately 10% of breast cancer incidence in the western world (Lillie et al., 2007).
Although there has been a substantial improvement in the outcome of breast cancer during the past several decades, primarily due to early diagnosis and increased use of hormonal and adjuvant chemotherapies, preventive approaches using pharmacological and other novel agents could be considered as the winning strategy in reducing the morbidity and mortality of breast cancer
Amoorain is isolated from the stem bark of the Indian medicinal plant Amoora rohituka, the product exhibits cytostatic as well as cytotoxic effects in human neoplastic hematopoetic and epithelial cells of diverse origin. Amoorain has also been shown to possess growth inhibitory and apoptosis-inducing effects in several mammary carcinoma cells of human origin. In animal studies, AMR significantly inhibited the growth of xenografted SW 620 colon carcinoma in mice and reduced tumor size in in rats. Amoorain has also been shown to inhibit the growth of human acute lymphoblastic leukemia cells by pro-apoptotic mechanisms and improve the survival of mice bearing Dalton’s lymphoma ascites tumor cells.
EnzymeBioSystems has found a method for the synthesis of pure Amoorain. The discovery of the method for large-scale synthesis of Amoorain represents a key breakthrough as it eliminates the need of using plant material and hence the dependency on the nature. It also creates the opportunity for animal studies to explore the chemopreventive efficacy of Amoorain.
It is now the Company’s goal to complete animal testing of its synthetic Amoorain to demonstrate its efficacy and lack of toxicity. If the animal studies prove to be successful, the Company plans to submit an IND (Investigational New Drug) application with the FDA to begin Phase I human studies.